Literature DB >> 31286487

Stereospecific interactions between histidine and monoclonal antibodies.

Youngbin Baek1,2, Parinaz Emami1, Nripen Singh3, Andrew Ilott4, Erinc Sahin4, Andrew Zydney1.   

Abstract

Histidine is a frequently used buffer in the final formulation of many commercialized monoclonal antibodies (mAbs), with histidine helping to stabilize the antibody during storage in addition to its buffering function. The objective of this study was to examine the stereospecificity of any histidine-antibody interactions using a combination of experimental studies and molecular dynamics simulations. Isothermal titration calorimetry provided evidence of weak stereospecific interactions, with the antibody showing approximately two to four additional interaction sites for d- versus l-histidine. The greater interactions with d-histidine were confirmed by measurements of the net protein charge using electrophoretic light scattering. The reduction in the net negative charge of the antibody in d-histidine led to significantly different behavior during diafiltration due to Donnan exclusion effects. Molecular dynamics simulations corroborated the presence of additional d-histidine interaction sites. These results provide the first demonstration of weak stereospecific interactions between l- and d-histidine and a mAb and the implications of these interactions for antibody formulation.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  buffer interactions; formulation; histidine; monoclonal antibody; stereospecificity

Year:  2019        PMID: 31286487     DOI: 10.1002/bit.27109

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  1 in total

1.  Understanding the Stabilizing Effect of Histidine on mAb Aggregation: A Molecular Dynamics Study.

Authors:  Suman Saurabh; Cavan Kalonia; Zongyi Li; Peter Hollowell; Thomas Waigh; Peixun Li; John Webster; John M Seddon; Jian R Lu; Fernando Bresme
Journal:  Mol Pharm       Date:  2022-08-10       Impact factor: 5.364

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.